ASP Isotopes (NASDAQ:ASPI) COO Sells $97,500.00 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $3.90, for a total value of $97,500.00. Following the completion of the transaction, the chief operating officer directly owned 2,256,879 shares of the company’s stock, valued at $8,801,828.10. The trade was a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Robert Ainscow also recently made the following trade(s):

• On Monday, June 8th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The stock was sold at an average price of $7.00, for a total value of $59,066.00.

ASP Isotopes Price Performance

ASPI opened at $4.20 on Monday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.85 and a current ratio of 3.87. The company has a market cap of $643.90 million, a price-to-earnings ratio of -3.18 and a beta of 3.59. ASP Isotopes Inc. has a one year low of $3.51 and a one year high of $14.49. The business’s fifty day moving average is $4.37 and its two-hundred day moving average is $5.20.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%. The firm had revenue of $5.12 million during the quarter, compared to analysts’ expectations of $4.47 million.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ASPI shares. Wall Street Zen upgraded shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $13.00.

Institutional Trading of ASP Isotopes

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in ASP Isotopes during the 3rd quarter worth about $34,000. BNP Paribas Financial Markets lifted its holdings in ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after purchasing an additional 2,548 shares in the last quarter. State of Wyoming acquired a new stake in shares of ASP Isotopes during the 1st quarter worth about $29,000. Allworth Financial LP acquired a new stake in shares of ASP Isotopes during the 2nd quarter worth about $51,000. Finally, Legal & General Group Plc raised its position in shares of ASP Isotopes by 30.4% in the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after buying an additional 1,953 shares during the last quarter. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.